New insider activity at Tandem Diabetes Care ( (TNDM) ) has taken place on August 11, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a notable move, Tandem Diabetes Care’s leadership has shown confidence in the company’s future by purchasing significant amounts of its stock. President & CEO John Sheridan acquired 10,000 shares, investing $102,300, while EVP & CFO Leigh Vosseller purchased 13,720 shares, amounting to $149,273. These transactions highlight a strong vote of confidence from the top executives.
Recent Updates on TNDM stock
Tandem Diabetes Care has experienced several price target adjustments from analysts due to a mix of positive and challenging developments. Lake Street downgraded the stock citing the need for faster U.S. growth and improved margins to support profitability. Barclays sees the stock as oversold post-earnings, offering a buying opportunity despite a slight target reduction. TD Cowen lowered its target, reflecting concerns over increased U.S. competition and moderated sales growth, while still appreciating the company’s long-term potential. The company’s recent earnings call highlighted robust international growth and product development, but also noted challenges in the U.S. market, including competition and sales growth moderation. Tandem’s FDA clearance for its SteadiSet infusion set and strategic initiatives in product development and pharmacy channel expansion underscore its commitment to innovation and long-term growth.
Spark’s Take on TNDM Stock
According to Spark, TipRanks’ AI Analyst, TNDM is a Neutral.
Tandem Diabetes Care’s overall stock score reflects significant financial challenges, including high leverage and negative cash flow, which weigh heavily on the score. Technical indicators suggest bearish momentum, further impacting the stock’s outlook. Despite these challenges, positive earnings call guidance and recent corporate events provide some optimism for future growth and market expansion.
To see Spark’s full report on TNDM stock, click here.
More about Tandem Diabetes Care
YTD Price Performance: -68.67%
Average Trading Volume: 1,825,758
Technical Sentiment Signal: Sell
Current Market Cap: $758.8M